ARTICLE | Finance
Seeing blockbuster in rare disease prompted Jeito to lead Azafaros’ €132M series B
The European firm’s Rafaèle Tordjman sees $1B sales, ‘exit optionality’ in a treatment for multiple lysosomal storage indications
May 16, 2025 3:11 PM UTC
European VC Jeito added to its rare disease portfolio by leading a new €132 million ($148 million) series B round for Dutch start-up Azafaros, supporting a pair of Phase III studies for lysosomal storage disorders.
Jeito Capital’s Rafaèle Tordjman told BioCentury that the firm typically looks for products that could generate at least $1 billion in peak sales, and said nizubaglustat (AZ-3102) from Azafaros B.V. has potential to reach that threshold if it reaches the market in multiple indications...